Hypotension with intravenous immunoglobulin therapy: importance of pH and dimer formation.
Therapy with intravenous immunoglobulin preparations has been used effectively in a wide range of conditions. Although generally well tolerated, intravenous immunoglobulin preparations may be associated with transient hypotension in some patients. This study examined the role of different immunoglobulin G fractions in the development of intravenous immunoglobulin-induced hypotension in an anaesthetized rat model and assessed the effects of a new liquid immunoglobulin prepared at a low pH on both the formation of immunoglobulin G dimers and the development of hypotension. The effects of this new preparation in an experimental autoimmune encephalomyelitis model were also evaluated. Results from the haemodynamic studies indicated that immunoglobulin G dimers in polyclonal immunoglobulin G are responsible for the hypotensive events associated with some immunoglobulin preparations. They also showed that adjustment to an acidic pH results in the rapid dissociation of immunoglobulin G dimers and prevents the development of hypotension. Additional experiments demonstrated that only immunoglobulin G dimers with a functional Fc fragment can bind to Fcgamma receptors on macrophages to induce the release of blood pressure-lowering mediators. Moreover, essentially monomeric Fc fragments can block the blood pressure-lowering effects of immunoglobulin G dimers. Preparation of a new liquid intravenous immunoglobulin with the pH adjusted to 4.3 prevents the formation of immunoglobulin G dimers even over long-term storage and does not significantly affect blood pressure in a rat model. This preparation is as effective as other intravenous immunoglobulin preparations in ameliorating symptoms of experimental autoimmune encephalomyelitis. These results, like those from previous studies, indicate that preparation of intravenous immunoglobulin at a low pH substantially reduces immunoglobulin G dimerization; this effect significantly decreases the potential for intravenous immunoglobulin to induce hypotension without reducing its clinically relevant biological activity.
Kroez
Monika
M
Aventis Behring GmbH, Emil von Behring Strasse 76, 35041, Marburg, Germany.
Kanzy
Ernst Jürgen
EJ
Gronski
Peter
P
Dickneite
Gerhard
G
D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000737:chemistry; D001688:Biological Products / Q000737:chemistry / Q000302:isolation & purification / Q000633:toxicity; D001794:Blood Pressure / Q000187:drug effects; D019281:Dimerization; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000503:physiopathology / Q000628:therapy; D005260:Female; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007022:Hypotension / Q000209:etiology* / Q000276:immunology / Q000517:prevention & control; D007141:Immunoglobulin Fc Fragments / Q000737:chemistry; D007130:Immunoglobulin Idiotypes / Q000737:chemistry; D016756:Immunoglobulins, Intravenous / Q000737:chemistry / Q000302:isolation & purification / Q000633:toxicity*; D051381:Rats; D011917:Rats, Inbred Lew; D017207:Rats, Sprague-Dawley
D000888:Antibodies, Anti-Idiotypic; D001688:Biological Products; D007141:Immunoglobulin Fc Fragments; D007130:Immunoglobulin Idiotypes; D016756:Immunoglobulins, Intravenous